expansion – Page 4

CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications

9 months ago talkbio0Tagged CordenPharma, Diabetes, Drug Industry, expansion, Glucagon-Like Peptide 1, Investments, Obesity, Peptides

CordenPharma, GLP-1, peptide manufacturing, expansion, investment, diabetes, obesity, pharmaceutical industry

Lilly’s Zepbound Shows Promise in Resolving Sleep Apnea in Obese Patients, Strengthening Case for Label Expansion

10 months ago talkbio0Tagged Approved, Eli, Eli Lilly, expansion, Labels (device), Obesity, Sleep Apnea Syndromes, SURMOUNT-OSA program, United States Food and Drug Administration, Zepbound

Zepbound, tirzepatide, sleep apnea, obesity, label expansion, Eli Lilly, SURMOUNT-OSA program, weight loss, FDA approval

Amylyx Acquires GLP-1 Receptor Antagonist for $35M to Fill Pipeline Gap

10 months ago talkbio0Tagged Amylyx, Amyotrophic Lateral Sclerosis, Biopharma, Eiger, expansion, GLP-1 receptor antagonist, pipeline, Relyvrio, Wolfram Syndrome

Amylyx Pharmaceuticals, Relyvrio, GLP-1 receptor antagonist, Eiger Biopharma, pipeline expansion, ALS, Wolfram syndrome

Syncona Expands Portfolio with Investments in iOnctura and Yellowstone, Two Cancer-Focused Biotechs

10 months ago talkbio0Tagged Biotechnology, cancer biotechs, expansion, Investments, iOnctura, portfolio, Syncona, Yellowstone

Syncona, iOnctura, Yellowstone, cancer biotechs, portfolio expansion, investment, biotechnology

Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC

10 months ago talkbio0Tagged Acquisition (action), Antibody-Drug Conjugates, Biopharma, biotech, Daily, expansion, MabCare, Malignant Neoplasms, pipeline, PTK7 protein, human

Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion

Amgen’s Uplizna Achieves Phase 3 Success in Treating Immunoglobulin G4-Related Disease, Paving Way for Label Expansion

11 months ago talkbio0Tagged amgen, Autoimmune Diseases, expansion, Immunoglobulin G4-Related Disease, Infrequent, Labels (device), Phase 3, Uplizna

Amgen, Uplizna, Phase 3, Immunoglobulin G4-Related Disease, IgG4-RD, Rare Autoimmune Disease, Label Expansion

Biogen Expands Immunology Portfolio with $1.15 Billion Acquisition of HI-Bio

11 months ago talkbio0Tagged Acquisition (action), Biogen, Drug Development, expansion, HI-Bio, Immunology

Biogen, HI-Bio, acquisition, immunology, $1.15 billion, expansion, therapeutics, drug development

AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030

11 months ago talkbio0Tagged AstraZeneca, Biotechnology, Drug Development, Drug Industry, expansion, growth strategy, healthcare innovation, Market

AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.

AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility

11 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, expansion, Facility (object), Generalized, innovation, Investments, Singapore

AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.

Rapport Neuroscience Biotech Aims for Expansion with Initial Public Offering

11 months ago talkbio0Tagged clinical-stage, expansion, IPO, mental health, nervous system disorder, Neuroscience discipline, Rapport

Rapport, neuroscience, biotech, IPO, clinical-stage, expansion, pharmaceuticals, neurological disorders, mental health